Kaiqi Liu

Nov 19, 2024 | nature.com | Kaiqi Liu

Dear Editor,In recent years, Venetoclax (Ven) has gained a prominent position in the treatment of newly diagnosed acute myeloid leukemia (AML) patients. Combinations of Ven with hypomethylating agents (HMA), Azacitidine (AZA) or decitabine (DEC), have become the first-line treatment for newly diagnosed AML patients who are elderly or not suitable for intensive chemotherapy (IC), with CR rates around 60–70% [1,2,3].

Apr 18, 2024 | mdpi.com | Kaiqi Liu |Ji Yuan Wu |Qing Sun |Haiyan Yang

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.